Penumbra Inc

PEN - CIK 0001321732

Market cap$12.56 B

Rank#817

SEC filings937

Penumbra Inc trades as PEN and has a market capitalization of $12.56 B, making it the #817 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.40B, up 17.5% from the prior year and net income of $177.69M. This page tracks Penumbra Inc through 937 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$1.40BFY 2025

Net income (latest FY)$177.69MFY 2025

Operating cash flow (latest FY)$238.66MFY 2025

Total assets (latest FY)$1.83BFY 2025

Gross margin67.1%latest FY

Net margin12.7%latest FY

Financial performance

Over the last 9 fiscal years Penumbra Inc's revenue grew from $263.32M to $1.40B, a compound annual growth rate of 20.4%. Net profit margin expanded from 5.6% to 12.7% over the same period - every figure below comes from the company's audited annual filings.

PEN annual revenueView details

Key statistics

Market cap: $12.56 B
Share price (derived)market cap / shares outstanding: $319.34
P/E ratio (trailing FY): 70.7
EPS (diluted)FY 2025: $4.52
Shares outstandingas of 2026-04-22: 0.04B
Total equityas of 2026-03-31: $1.47B
Return on equity: 12.1%
Cash & equivalentsas of 2026-03-31: $241.29M

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-21
425	-	2026-05-07
Major company event	8-K	2026-05-07
Quarterly report	10-Q	2026-05-06
Major company event	8-K	2026-05-06
SCHEDULE 13G	-	2026-04-30
Proxy materials	DEFA14A	2026-04-29
Proxy statement	DEF 14A	2026-04-29

Browse the full filing history (937 filings)

Recent press releases

Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results2026-02-25
ALAMEDA, Calif. , Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. ( NYSE: PEN ) , the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Boston Scientific announces agreement to acquire Penumbra, Inc.2026-01-15
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results2026-01-15
ALAMEDA, Calif. , Jan. 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), the world's leading thrombectomy company, today announced certain unaudited and preliminary financial results for the fourth quarter and full year 2025.
Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference2025-12-29
ALAMEDA, Calif. , Dec. 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.
Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference2025-11-19
ALAMEDA, Calif. , Nov. 19, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Piper Sandler 37 th Annual Healthcare Conference on Wednesday, December 3, 2025.

Similar companies

The largest companies sharing Penumbra Inc's SEC industry classification (surgical & medical instruments & apparatus).

SYKStryker Corporation$117.82 B PEN vs SYK

MMM3M Company$81.87 B PEN vs MMM

BSXBoston Scientific Corporation$71.33 B PEN vs BSX

MDLNMedline Inc.$49.12 B PEN vs MDLN

BDXBecton, Dickinson and Company$41.03 B PEN vs BDX

Frequently asked questions

What is Penumbra Inc's market cap?

Penumbra Inc (PEN) has a market capitalization of $12.56 B as of 2026-06-10, ranking #817 among US-listed companies.

How much revenue does Penumbra Inc make?

Penumbra Inc reported revenue of $1.40B for fiscal year 2025, an increase of 17.5% year over year.

Is Penumbra Inc profitable?

Yes. Penumbra Inc reported net income of $177.69M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.